Vitamin E and Vitamin B12: study protocols
16 study groups took Vitamin E together with Vitamin B12. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin E
11 study groups in 9 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg and 25 mg to 50 mg, 27% of 11 study groups each.
| Daily dose | Study groups |
|---|---|
| 5 mg or less | 1 |
| 5 mg to 10 mg | 2 |
| 10 mg to 25 mg | 3 |
| 25 mg to 50 mg | 3 |
| 50 mg to 100 mg | 1 |
| 100 mg to 250 mg | 0 |
| over 250 mg | 1 |
Dose per serving from research: Vitamin B12
16 study groups in 12 studies say how much Vitamin B12 participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 mcg to 5 mcg, 50% of 16 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mcg or less | 1 |
| 1 mcg to 2.5 mcg | 2 |
| 2.5 mcg to 5 mcg | 8 |
| 5 mcg to 10 mcg | 3 |
| 10 mcg to 25 mcg | 0 |
| 25 mcg to 50 mcg | 0 |
| 50 mcg to 100 mcg | 0 |
| 100 mcg to 250 mcg | 0 |
| 250 mcg to 500 mcg | 1 |
| 500 mcg to 1 mg | 1 |
Commonly used together
16 of 16 study groups took Vitamin E and Vitamin B12 with something else. Shown: what 3 or more different studies gave. The 10 most common of 13.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Folic Acid | 14 |
| Vitamin B6 | 11 |
| Vitamin C | 10 |
| Zinc | 8 |
| Selenium | 6 |
| Vitamin D | 6 |
| Copper | 5 |
| Iron | 5 |
| Vitamin A | 5 |
| Iodine | 4 |
16 study groups
| Study | ||||
|---|---|---|---|---|
| Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly 2004 · special nutritional formula · Healthy adults aged 70 years or older with Mini Mental score ≥22 | 120 IU | 3.8 mcg | 1 year | 30 |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 8 mg | 2 mcg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 10 mg | 2.6 mcg | — | — |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 3-month blinded trial · Community-dwelling adults aged 18–86 years, both sexes, without dementia or clinical memory difficulties | 30 IU | 6 mcg | 90 days | 59 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · Open-label NF group, separate 6-month trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 30 IU | 6 mcg | 26 weeks | 38 |
| Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy 2024 · 10-element combination tablet · Overweight or obese adults with type 2 diabetes and mild-to-moderate painful diabetic neuropathy; mean age 63 years | 15 mg | 5 mcg | 26 weeks | 36 |
| A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia 2010 · NF group, 2-week blinded trial · Community-dwelling adults, both sexes, without dementia or clinical memory difficulties | 30 IU | 6 mcg | 2 weeks | — |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 15 mg | 2.6 mcg | 165 days | 749 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 40 mg | 3 mcg | 24 weeks | 501 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 40 mg | 3 mcg | 24 weeks | 201 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 15 mg | 2.6 mcg | — | 176 |
| Multiple Micronutrient Powder Reduces Vitamin E Deficiency in Brazilian Children: A Pragmatic, Controlled Clinical Trial 2019 · intervention group · Children aged 6–9 months at the start of the study, male or female, attending primary health care centers in Goiânia, Brazil | 5 mg | 0.9 mcg | 90 days | 107 |
| Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial 2006 · Antioxidant vitamins plus B-group vitamins · Acute ischemic stroke patients treated within 12 hours of symptom onset | 800 IU | 400 mcg | 2 weeks | 24 |
| Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD 2009 · Treatment group · Adults with stage 2 to 4 chronic kidney disease and creatinine clearance of 15 to 70 mL/min/1.73 m² | 300 mg | 1 mg | 2 years | 47 |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG1 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 45 mg | 2.5 mcg | 12 weeks | 30 |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG2 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 90 mg | 5 mcg | 6 weeks | 30 |